Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Safety of AJU-B718 and B718R in Healthy Adults
NCT07901088Phase 1Not yet recruiting
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Peripheral Arterial Disease (PAD) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07901088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901088.